Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The Glucose Pie Chart report shows in graphical format what percent of your readings within a given time period are within, below or above your Glucose Target levels. You can choose the last 1, 7, 14, 30 or 90 days.
An internet connection is required to download the app and to receive remote glucose values for display on your Eversense® NOW App.
You can view a snapshot of the Home screen on your iOS device if you add the Eversense® App widget to your widget page. For information on managing widgets, consult your iOS device user guide.
You can view a snapshot of the Home screen on your Android device if you swipe down on your device to show the notification tray. The app must be running in the background. This will show you the latest glucose.
Eversense gives you real-time glucose readings through a small sensor that’s placed just under the skin of your upper arm by a healthcare professional. The smart transmitter sits above the sensor, sending glucose data to your app. Want to learn more about the science behind Eversense? Check out our “How Eversense Works” video!
You do not need to change the battery. The Eversense® E3 Smart Transmitter has a rechargeable battery and is reusable for up to one year. After one year, the warranty expires and the transmitter should be replaced with a new transmitter.
The Eversense® E3 CGM system consists of three main components: a glucose sensor, a Smart Transmitter, and a Mobile Medical Application to read the glucose data.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1